Skip to main content
Jafron Biomedical Co.,Ltd. logo

Jafron Biomedical Co.,Ltd. — Investor Relations & Filings

Ticker · 300529 ISIN · CNE100002995 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,842 across all filing types
Latest filing 2022-02-11 Declaration of Voting R…
Country CN China
Listing Shenzhen Stock Exchange 300529

About Jafron Biomedical Co.,Ltd.

https://www.jafron.com

Jafron Biomedical Co.,Ltd. specializes in the research, development, and manufacturing of biomaterials and equipment for blood purification. The company is a primary provider of hemoperfusion technology, focusing on the production of adsorbent cartridges designed to remove specific toxins and inflammatory mediators from the bloodstream. Its core product portfolio includes the HA series of hemoperfusion cartridges, which are applied in clinical settings for end-stage renal disease, acute poisoning, critical care, and liver failure. Beyond consumables, the company develops blood purification machines and integrated treatment systems. These solutions target clinical applications in nephrology, intensive care, and hepatology. By leveraging advanced resin adsorption technology, the company provides specialized extracorporeal blood treatment options aimed at improving patient outcomes in complex medical conditions.

Recent filings

Filing Released Lang Actions
国浩律师（深圳）事务所关于公司2022年第一次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the convening, procedures, and results of the 2022 first extraordinary general meeting (临时股东大会) of the company. It details the legality of the meeting notice, the qualifications of attendees, the voting procedures, and the voting results on several resolutions including stock option plans and amendments to the company charter. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to a shareholders' meeting. It is not a simple announcement but a detailed legal opinion on the meeting and its resolutions. This fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it includes official voting results and related legal validation of the shareholder meeting.
2022-02-11 Chinese
监事会关于2022年股票期权激励计划首次授予激励对象名单的核查意见及公示情况说明
Regulatory Filings Classification · 95% confidence The document is a public announcement by the supervisory board regarding the verification and public disclosure of the initial list of incentive recipients under the company's 2022 stock option incentive plan. It includes details about the public notice period, verification procedures, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial data, nor is it a report of financial results or management discussion. It is a regulatory announcement related to corporate governance and compliance with stock option incentive regulations. Given the nature of the content and the absence of financial data or report format, this document fits best under Regulatory Filings (RNS). The document length is short (1715 characters), and it is an announcement rather than a full report.
2022-01-28 Chinese
关于控股股东、实际控制人增持公司股份计划的进展公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the progress of a shareholding increase plan by the controlling shareholder and actual controller of the company. It details the number of shares purchased, the percentage of total shares, the monetary amount involved, and the compliance with relevant regulations. There is no financial statement or comprehensive financial report included. The document is focused on the update of a capital increase plan by a major shareholder, which fits the category of Major Shareholding Notification (MRQ). The document length is 2312 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is MRQ.
2022-01-23 Chinese
2022年股票期权激励计划（草案）摘要
Board/Management Information Classification · 95% confidence The document is a detailed plan regarding a 2022 stock option incentive plan for a company named 健帆生物科技集团股份有限公司. It includes legal references, definitions, purpose, management structure, scope of incentive recipients, number and allocation of stock options, terms of validity, exercise price, exercise conditions, performance assessment criteria, and adjustment procedures. The document is comprehensive and lengthy (15,000 characters), containing substantive content about the stock option incentive plan rather than just an announcement or summary. It is not a financial report like an annual or interim report, nor is it a regulatory filing or announcement. It is a detailed management-level document about stock option incentives, which falls under the category of Board/Management Information (MANG) because it relates to management decisions and plans about executive compensation and incentives. Therefore, the appropriate classification is MANG with high confidence.
2022-01-17 Chinese
2022年股票期权激励计划（草案）
Regulatory Filings Classification · 95% confidence The document is a detailed plan for a 2022 stock option incentive scheme by 健帆生物科技集团股份有限公司. It includes legal references, definitions, objectives, management structure, scope of incentive recipients, number and allocation of stock options, terms of validity, exercise price, exercise conditions, and performance assessment criteria. The content is comprehensive and regulatory in nature, focusing on the stock option incentive plan itself rather than a simple announcement or summary. It is not a financial report, earnings release, or management discussion, but a formal incentive plan document. This type of document fits best under the category of Regulatory Filings (RNS) because it is a regulatory disclosure about a stock option incentive plan, which does not fall under other more specific categories like Capital/Financing Update or Board/Management Information. The document is lengthy (15,000 characters) and contains substantive content, not just an announcement or certification. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2022-01-17 Chinese
第四届监事会第二十七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 27th meeting of the 4th Supervisory Board of the company, including approval of a 2022 stock option incentive plan and related matters. It contains no financial statements or detailed financial data, but rather governance and supervisory board decisions. The document references the disclosure of detailed plans on a regulatory website but does not itself contain the full plan or financial report. The content is about board/supervisory decisions and approvals, not an annual or interim report, earnings release, or capital update. It is not a proxy solicitation or voting result announcement. The document is best classified as Board/Management Information (MANG) because it reports on supervisory board meeting resolutions and governance-related approvals.
2022-01-17 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.